Management Team
The experienced executive team at BiPar Sciences consists of veteran industry and clinical leaders who are working together to transform cancer therapy. Building on their collective expertise and extensive collaborative networks, the group has significant leadership capabilities for growing a successful biopharmaceutical company.
- Atul Dhir, M.D., Ph.D. / Chief Executive Officer
Dr. Dhir is a physician and a scientist with extensive experience in leading health care companies. Most recently, he was a senior executive at US Oncology, the largest provider of cancer care in the US. At US Oncology, Dr. Dhir was the President of the Cancer Research Group, one of the leading cancer clinical drug development companies in the US. He was also the Executive Vice President and General Manager of several other cancer-related businesses in the company. Prior to US Oncology, Atul was a Vice President of the health care division of Monsanto and a consultant with McKinsey and Company.
Dr. Dhir received his medical degree from the prestigious All India Institute of Medical Sciences, New Delhi, India, and his Ph.D. from Oxford University, UK, where he studied as a Rhodes Scholar.- Charles Bradley, Ph.D. / Vice President, Clinical Development
Dr.Bradley joined BiPar Sciences in April 2005 as Vice President, Clinical Development. From 2000 to 2005, Dr. Bradley held a variety of positions with Amgen, both in the Medical Affairs and Clinical Development organizations. He had overall clinical operational responsibilities for programs across the oncology and nephrology therapeutic areas.
Prior to joining Amgen, Dr. Bradley held senior positions in the clinical development group at Guilford Pharmaceuticals and in the Clinical Pharmacology department at Hoechst-Roussel Pharmaceuticals. Dr. Bradley also served as a pharmacokinetic reviewer for more than three years with the U.S. Food and Drug Administration.
Dr. Bradley received his Ph.D. in Bioanalytical Chemistry from the University of Delaware, and obtained post-doctoral training in clinical pharmacology from the Uniformed Services University in Bethesda, Maryland. He also is a board-certified diplomate in Applied Pharmacology of the American Board of Clinical Pharmacology.- Anne Blackwood-Chirchir, M.D. / Vice President, Medical Development
Dr. Blackwood-Chirchir joinedBiPar Sciences in September 2009 as Vice President of Medical Development. Dr. Blackwood-Chirchir has extensive experience in clinical oncology, having served as a Group Medical Director at Genentech, where she was the Development Sub-team Leader for Herceptin,and managed those responsible for clinical and strategic development ofother HER2-targeted agents. Prior to joining Genentech, Dr.Blackwood-Chirchir held medical director positions at Bristol-Myers Squibb, serving as the clinical pharmacology/translational medicine lead for the development of dasatinib and the co-leader for the early development team focused on small molecule signal-transduction targeted tyrosine kinase inhibitors in oncology.
Prior to joining industry, Dr. Blackwood-Chirchir served for 7 years on the faculty at the University of Pennsylvania in the Division of Hematology-Oncology within the Department of Medicine and the Department of Biostatistics and Epidemiology.
Dr.Blackwood-Chirchir received her A.B. degree in Biochemistry and Molecular Biology at Harvard-Radcliffe College, and her M.D. at Columbia University. She completed her residency in internal medicine at Albert Einstein College of Medicine, a postdoctoral research fellowship at Columbia University's Comprehensive Cancer Center and School of Public Health, and a clinical oncology fellowship at the University of Pennsylvania in Philadelphia. She has contributed to over30 publications in the scientific literature, predominantly within the field of medical oncology.- Deborah A.Thomas, Ph.D. / Vice President, Regulatory Affairs
Dr. Thomas joined BiPar Sciences in October 2007 as Vice President, Regulatory Affairs. Prior to joining BiPar Sciences, Dr. Thomas spent the previous 17 years at Genentech, where she held senior positions in Toxicology, Product Portfolio Management, and Regulatory Affairs. As a senior director in Regulatory Affairs, Dr. Thomas oversaw products moving from late-stage research and development into Phase I clinical testing. Prior to that, she served as Project Team Leader for Avastin, pertuzumab and Raptiva in the Product Portfolio Management Department.
Prior to joining Genentech, Dr. Thomas began her career in the pharmaceutical industry as a toxicologist at Syntex Research.
Dr.Thomas received her Ph.D. in Toxicology and her B.S. in Microbiology from the University of Kentucky. She completed her postdoctoral training at the Chemical Industry Institute of Toxicology (CIIT) in Research Triangle Park, North Carolina. She is also a board-certified diplomate of the American Board of Toxicology.